Bristol-Myers (BMY), Calithera Biosciences (CALA) Expand Collaboration Evaluating Opdivo in Combination with CB-839 for NSCLC May 10, 2017 07:01AM
Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma May 10, 2017 06:59AM
Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma May 10, 2017 06:59AM
Incyte (INCY) and Calithera Biosciences (CALA) Enter Pact to Develop and Commercialize CB-1158 Jan 30, 2017 06:49AM
Incyte (INCY), Calithera Biosciences (CALA) Enter Collaboration to Develop and Commercialize CB-1158 Jan 30, 2017 06:48AM


Jan 30, 2017 06:45AM Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Jan 30, 2017 06:45AM Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Dec 21, 2016 07:01AM Bristol-Myers Squibb (BMY) and Calithera Biosciences (CALA) Enter Pact to Evaluate Opdivo in Combination with CB-839 in ccRCC
Dec 21, 2016 06:59AM Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
Dec 21, 2016 06:59AM Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
Jun 12, 2015 09:30AM Pre-Open Stock Movers 06/12: (ESI) (BOBE) (TWTR) Higher; (LF) (AVEO) (XONE) Lower (more...):